A “case –report” from NorDiag, which shows the capability of GenefecTM, is accepted for publication in a leading European medical journal. The test can identify early stages of bowel cancer long before alternative methods, and the accepted “case report” is reporting on such an incident where the patient was recovered after simple surgery. The report demonstrates how useful regularly testing with a genetic marker as GenefecTM can be for members of risk groups of bowel cancer.

“This report shows how useful genetic testing can be for individuals when it comes to preventing the development of bowel cancer,” says CEO of NorDiag, Christian Horn. “The conclusions from this study are important for the company for further market development for our genetic test, both in the diagnostic markets, and in the emerging markets for screening of larger segments of the population,” he continues.

One million people are affected yearly of bowel cancer, and despite improvements in diagnostics and treatment, not more than half of the patients survive. Survival rates increases with early detection, and costs of treatment are reduced. NorDiag’s GenefecTM identifies a substantial part of the early stages to bowel cancer.

- Samples of faeces for genetic testing are easy for the patients to collect, and the test is very accurate when it comes to identification of early stages of bowel cancer, says professor Dagfinn Øgreid, clinical director in NorDiag and one of the authors of the ”case report”.

For further information, please contact;
CEO Christian Horn in NorDiag ASA, phone: +47 90 16 31 53

About NorDiag ASA:
NorDiag is a biotechnology company with focus on early detection of cancer. The company`s first products are Genefec and GeneOpsy, for genetic diagnostics of colorectal cancer. In addition the company has R&D programmes for new technology and products for lung- and pancreatic cancer. NorDiag is listed on the Oslo Stock Exchange with the ticker NORD. See www.nordiag.no